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Abstract
Background A tool for diagnosing childhood cerebellar tumours using magnetic resonance (MR) spectroscopy peak height
measurement has been developed based on retrospective analysis of single-centre data.
Objective To determine the diagnostic accuracy of the peak height measurement tool in a multicentre prospective study, and
optimise it by adding new prospective data to the original dataset.
Materials and methods Magnetic resonance imaging (MRI) and single-voxelMR spectroscopywere performed on children with
cerebellar tumours at three centres. Spectra were processed using standard scanner software and peak heights for N-acetyl
aspartate, creatine, total choline and myo-inositol were measured. The original diagnostic tool was used to classify 26 new
tumours as pilocytic astrocytoma, medulloblastoma or ependymoma. These spectra were subsequently combined with the
original dataset to develop an optimised scheme from 53 tumours in total.
Results Of the pilocytic astrocytomas, medulloblastomas and ependymomas, 65.4% were correctly assigned using the original
tool. An optimized scheme was produced from the combined dataset correctly assigning 90.6%. Rare tumour types showed
distinctive MR spectroscopy features.
Conclusion The original diagnostic tool gave modest accuracy when tested prospectively on multicentre data. Increasing the
dataset provided a diagnostic tool based on MR spectroscopy peak height measurement with high levels of accuracy for
multicentre data.
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Introduction
1H magnetic resonance (MR) spectroscopy measures the con-
centration of metabolites in a preselected volume of tissue.
Although numerous studies in adults and a smaller number
in children have shown MR spectroscopy metabolite profiles
to be helpful in the noninvasive assessment of brain tumours
[1–12], the technique is currently not widely used in a clinical
paediatric setting.
MR spectroscopy is difficult to analyse and its application
is hindered by the lack of straightforward analysis tools. The
majority of published studies have been based on sophisticat-
ed data analysis techniques, including diagnostic classifiers [7,
11, 13, 14] and computerised pattern recognition [9–11,
15–17], which are not readily available to radiologists. In a
clinical setting, a fast, simple and easily implemented method
of data analysis would be of major benefit to make MR spec-
troscopy interpretation readily accessible to clinicians without
extensive knowledge about spectroscopy or dedicated com-
puter software.
MR spectroscopy can facilitate noninvasive diagnosis as
different brain tumour types display characteristic chemical
profiles [9]. Quantitative interpretation of individual metabo-
lites may determine tumour type and grade. Brain tumours are
characterized by high levels of total choline and lactate and
low levels of N-acetyl aspartate [11, 13], with high-grade tu-
mours having high total levels of choline, lipids [18] and gly-
c ine [19] . Taur ine is of ten present in pr imi t ive
neuroectodermal tumours [20] and medulloblastomas [10,
11]. Pilocytic astrocytomas generally display lower levels of
creatine than other paediatric brain tumours and have high
levels of lactate despite their benign nature [10, 21].
Interpreting MR spectroscopy using sophisticated pattern rec-
ognition techniques, such as principal component analysis,
linear discriminant analysis and artificial neural networks [3,
17], has been found to be highly accurate in brain tumour
classification.
It is important to develop and evaluate simple and robust
analysis tools to allow implementation of MR spectroscopy in
a routine clinical setting. A recent retrospective study found
that including visual interpretation of MR spectroscopy in the
preoperative diagnosis of paediatric brain tumours significant-
ly improved accuracy of radiologic diagnosis over MRI alone
[22]. This is encouraging as it suggests MR spectroscopy may
be used clinically without sophisticated decision support
software.
We previously developed an analysis tool based on peak
height ratio calculation that accurately classified cerebellar
tumours using retrospective data [23], with the aim of provid-
ing a simple but robust technique for radiologists to use in a
clinical setting. The tool uses standard scanner manufacturer’s
software to produce anMR spectrum, followed by peak height
measurement and a straightforward set of rules to predict
histopathology. This tool correctly classified 26 of 27 spectra
from childhood cerebellar tumours, with agreement of 92.5%
among 4 blinded testers. There were, however, limitations in
that the dataset was small, with ependymomas poorly repre-
sented, and data were processed on a single dedicated scanner
in one centre.
Despite the increase in studies utilizing MR spectroscopy
in diagnosing brain tumours, there are few published prospec-
tive studies evaluating analysis tools. Prospective evaluation
is vital to determine true accuracy and provide information to
allow incorporation of techniques into routine clinical prac-
tice. It is difficult to ascertain generalisability of single-centre
studies. Prospective testing on a multicentre dataset will en-
able full evaluation, assess robustness to change of data source
and reduce bias. Acquiring a larger dataset may allow refine-
ment and expansion of the method.
The aim of this study was twofold: to prospectively deter-
mine the diagnostic accuracy of the previously developed
peak height measurement tool in a multicentre setting and to
optimize the tool by adding newly acquired data to the original
dataset.
Materials and methods
Data were accrued from patients presenting with cerebellar
lesions at one of three centres: Birmingham Children’s
Hospital, Queens Medical Centre, Nottingham, and the
Royal Marsden Hospital. All data were collected on 1.5-T
clinical MR systems, with scanners from Siemens (Siemens
Avanto 1.5 T; Siemens Healthcare, Erlangen, Germany),
General Electric (GE Signa EXCITE 1.5 T; GE Healthcare,
Chicago, IL) and Philips (Philips Ingenia 1.5 T; Philips
Healthcare, Best, the Netherlands). Ethical approval was ob-
tained from the East Midlands–Derby Research Ethics
Committee (REC 04/MRE04/41) and parental consent was
obtained. All scans were performed at diagnosis, before sur-
gery, chemotherapy or radiotherapy.
Single-voxel MR spectroscopy was performed using a stan-
dard point resolved spectroscopy (PRESS) sequence with a short
echo time (28–35ms) and a relaxation time of 1,500ms. A cubic
voxel of side length 1.5 or 2 cm was placed entirely within the
solid component of the tumour, avoiding cystic regions and areas
of haemorrhage or calcification (Fig. 1). One hundred twenty-
eight acquisitions were used for the larger voxels and 256 for the
smaller ones. MR spectroscopy was processed locally using
built-in scanner software, and quality control was applied as in
the original study [23]:
1) MR spectroscopy peaks must be sufficiently narrow for
the creatine (3.0 ppm [ppm]) and total choline (3.2 ppm)
peaks to be visually well separated.
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2) The choline peak height must be at least five times greater
than the level of noise.
As in the original classification scheme, peak heights were
measured using spectra produced by scanner software. Post-
processing was taken as that used routinely for clinical work
within each centre, and this was usually within the default
scanner settings. Spectra at Birmingham Children’s Hospital
were generated by standard Siemens Symphony NUM4 scan-
ner software (Siemens, Erlangen, Germany), which assigns
peaks for total choline, creatine, N-acetyl aspartate and myo-
inositol. Processed spectra from the Siemens Symphony at
Birmingham Children’s Hospital were viewed using
imageJ™, a standard Digital Imaging and Communications
in Medicine viewer available at http://rsb.info.nih.gov/ij/.
For data from other scanners, a screen capture was taken of
the spectrum, which was saved as a jpeg to be analysed using
the same method. In addition to the major metabolites
measured in the previous study (myo-inositol, total choline,
creatine and N-acetyl aspartate), peaks associated with reso-
nances due to lipids and macromolecules were measured at
both 0.9 and 1.3 ppm. A representative MR spectrum from a
normal mature paediatric brain is shown in Fig. 2.
The peak height was taken as the vertical distance between
the top of the peak and the baseline. The top of the peak was
identified visually as the maximum value within the frequency
range giving rise to the peak. Not all spectra had a flat baseline
largely due to variation in water suppression, differences in
post-processing between scanners and signals from macro-
molecules. Where the baseline was flat, peak heights were
all measured from a set baseline to the apex of each peak.
Where the baseline was not flat, the peak height was taken
from the base of the individual peak to the apex.
Measurements were repeated 3 times by an independent
researcher with experience in spectroscopy (L.M.H., with
3 years of experience) to reduce error. Ratios were generated
between peak heights for the six peaks measured.
Classification using original scanner classifier
Cases passing quality control were separated into four groups:
pilocytic astrocytoma, ependymoma, medulloblastoma and oth-
er, according to histopathological diagnosis. The tumours in the
first three groups, i.e. the three tumour classes used in the initial
scheme, were assessed using the original classification scheme
Fig. 2 An example 1H MR spectroscopy profile of normal brain (white
matter) acquired at 1.5 T shows metabolite peaks used in the analysis. a.u
arbitrary units, Cr creatine, LMM lipids and macromolecules, mInsmyo-
inositol,NAAN-acetyl aspartate, ppm parts per million, tCho total choline
Fig. 1 A 7-year-old girl with a
midline cerebellar tumour. Axial
(a) and sagittal (b) MR images
demonstrate positioning (white
rectangles) for single-voxel MR
spectroscopy acquisition
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[23]. Classification rates were determined for prospective data
both collected on the Siemens MRI scanner at Birmingham
Children’s Hospital and that collected on other scanners.
Determining the best metabolite ratios for tumour
discrimination using the whole dataset
An analysis assessed whether metabolite ratios used in the
original scheme remained optimal for distinguishing among
the three tumour types for the combined dataset. The method-
ology closely follows that developed in the previous study
[23]. In addition to metabolites used in the original study,
peaks associated with lipid and macromolecular signals were
measured at 1.3 ppm and 0.9 ppm (lipids and macromolecules
1.3 and lipids and macromolecules 0.9, respectively), and ra-
tios between these and total choline were generated. Analysis
of variance determined the significance of differences in the
means of all metabolite peak height ratios among the three
tumour types. Metabolite ratios with no significant difference
(P<0.05) among tumour groups were discarded. Receiver op-
erator characteristic (ROC) curves were generated for each of
the remaining metabolite ratios for each tumour type. The area
under the receiver operator characteristic curve (AUC) was
taken to be the best measure of accuracy of the test performed.
Scatterplots were created from metabolite ratios showing the
best discrimination to check distributions visually. Optimal
cutoff values for each of the chosen metabolite ratios were
taken as points of maximum sensitivity plus specificity.
Tumours that did not have a diagnosis of pilocytic astrocy-
toma, medulloblastoma or ependymoma were assessed for
their main spectral characteristics and the metabolite ratios
compared with those of the other three tumour groups using
scatterplots.
Assignment of peak heights
Analysis of spectral fits in the original dataset showed
that in many cases the entire broad peak at 2.0–2.5 ppm
was assigned to N-acetyl aspartate. As this broad peak
has contributions from lipids, macromolecules, glutamate
and glutamine, attribution of the whole peak to N-acetyl
aspartate results in gross overestimation of the N-acetyl
aspartate peak area. This was particularly evident when
there was no narrow N-acetyl aspartate peak at 2.0 ppm.
The values of N-acetyl aspartate/creatine obtained in the
30 ms and 135 ms echo time spectra were compared in
cases in the original dataset where data had been collect-
ed at both echo times to test the validity of attributing a
peak height at 2.0 ppm to N-acetyl aspartate. This
showed a significant correlation between N-acetyl
aspartate/creatine values at the two echo times (P<0.01).
Results
In the new cohort, MRI and short echo timeMR spectroscopy
were performed on 36 children with cerebellar lesions after
Feb. 16, 2005, at three centres. All patients underwent biopsy,
leading to a diagnosis of 13 pilocytic astrocytomas, 4
ependymomas, 14 medulloblastomas, 2 atypical teratoid
rhabdoid tumors, 1 ganglioglioma, 1 diffuse low-grade astro-
cytoma and 1 high-grade lesion of undetermined nature. Of
these, four pilocytic astrocytomas scanned on the Siemens
Symphony at Birmingham Children’s Hospital failed to pass
quality control, leaving a group of nine pilocytic astrocytomas
for further consideration. In addition, one medulloblastoma
case at the Royal Marsden Hospital was excluded due to in-
complete data, leaving 13medulloblastomas in the analysis. A
total of 31 patients were included, of which 26 had one of the 3
main tumour types. RepresentativeMR spectra for each of the
three main tumour types are shown in Fig. 3.
One spectrum, attributed to a pilocytic astrocytoma, ac-
quired at Queens Medical Centre on a Phillips system, had
very poor water suppression and screen capture had removed
the lower part of the screen. The spectrum was removed from
statistical analysis as peak heights could not be accurately
determined, although classification was undertaken to assess
whether poor quality data could yield reasonable
classification.
Classification using original scanner classifier
Of the 31 spectra that passed quality control, 26 were of one of
the 3 original disease types, leaving 5 spectra from tumours
with rare diagnoses not included in the original scheme.
Classification rates are summarised in Table 1. The original
classifier had a correct classification rate of 65.4% on the new
data (n=26), correctly classifying 5 of the 9 pilocytic
astrocytomass, 2 of the 4 ependymomas and 10 of the 13
medulloblastomas. The original classifier was subsequently
applied to the complete dataset of 53 tumours, comprising
26 from the new and 27 from the old cohorts. Overall, this
scheme had a classification rate of 81.1% using the complete
dataset.
Re-optimising cutoff values
Re-optimizing cutoff values for ratios in the original classifier
using a complete dataset of 52 spectra (a pilocytic astrocytoma
with poor water suppression was removed from optimization
stage) gave values of 2.22 for N-acetyl aspartate/creatine, 0.45
for creatine/total choline and 1.35 for myo-inositol/N-acetyl
aspartate, with an overall correct classification rate of 64.2%.
The classifier correctly classified 14 of 15 pilocytic astrocyto-
mas, with 4 medulloblastomas and no ependymomas
misclassified as pilocytic astrocytomas. The classification
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accuracy for pilocytic astrocytoma versus the combined group
of medulloblastoma and ependymoma was 48/53 (91%).
Seven of 8 ependymomas, but only 14 of 29 medulloblastoma
spectra, were correctly classified. Of misclassified medullo-
blastomas, 4 were classified as pilocytic astrocytoma and 11
as ependymoma.
Determining the best metabolite ratios for tumour
discrimination using the whole dataset
A new two-step classifier was developed from the
whole dataset as follows. The ratios offering the highest
significance separating pilocytic astrocytomas from the
other two tumour types were N-acetyl aspartate/total
choline, N-acetyl aspartate/creatine and myo-inositol/N-
acetyl aspartate, all of which had P-values <0.01
(Fig. 4). The ratios offering the most significant differ-
ence between ependymoma and medulloblastoma spectra
were creatine/total choline and myo-inositol/total cho-
line, both of which had P-values <0.01 (Fig. 4).
Results of the two-tailed t-tests can be seen in Table 2.
Findings were confirmed by calculating the AUC of ROC
curves for all ratios with P<0.01. AUCs for pilocytic astrocy-
toma against ependymoma+medulloblastoma (Table 3) re-
vealed 2 ratios with average AUCs greater than 0.9: myo-
inositol/N-acetyl aspartate and N-acetyl aspartate/creatine.
Fig. 3 Representative 1H MR
spectra for the three main tumour
types: (a) ependymoma, (b)
medulloblastoma and (c) pilocytic
astrocytoma. a.u arbitrary units,
Cr creatine, LMM lipids and
macromolecules, mIns myo-
inositol, NAA N-acetyl aspartate,
ppm parts per million, tCho total
choline
Table 1 Classification rates for
prospective evaluation of
classification scheme for
cerebellar tumours, based on peak
height measurement from spectra
produced by scanner software
Diagnosis Number of
patients
Correct
classification
(%)
Magnetic resonance spectroscopy classification
Pilocytic
astrocytoma
Ependymoma Medulloblastoma
Pilocytic
astrocytoma
9 60 5 1 3
Ependymoma 4 50 0 2 2
Medulloblastoma 13 80 3 0 10
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Both N-acetyl aspartate/creatine and myo-inositol/N-acetyl
aspartate were therefore included in stage 1 of the classifier.
AUCs for ependymoma against medulloblastoma (Table 3)
showed a very high AUC for myo-inositol/total choline, and
high AUCs for creatine/total choline and N-acetyl aspartate/
total choline. Stage 2 was constructed using myo-inositol/total
choline alone, with creatine/total choline and N-acetyl
aspartate/total choline as checks to verify class assignment.
Cutoff values were determined for all these ratios using the
following classification scheme (Fig. 5):
& Step 1: For a tumour to be assigned to the class of pilocytic
astrocytoma, N-acetyl aspartate/creatine > 2.22, and myo-
inositol/N-acetyl aspartate <0.65.
& Step 2: A tumour not classified as a pilocytic astrocytoma
is assigned to the class of medulloblastoma if myo-inosi-
tol/total choline <0.85.
This updated scheme gave a correct classification rate of
90.6% for the 3 main tumour types, correctly classifying 48 of
the 53 spectra (Table 4). Misclassifications include 1
ependymoma being classified as a medulloblastoma, 2 medul-
loblastomas as pilocytic astrocytomas, 1 medulloblastoma as
an ependymoma and the outlier pilocytic astrocytoma as an
ependymoma.
Other tumours of the cerebellum
Tumours with diagnoses other than pilocytic astrocytoma,
medulloblastoma or ependymoma form a diverse group.
There were four tumour types in the cohort. Values for each
of the ratios are shown in Table 5.
There were two atypical teratoid rhabdoid tumours in
the dataset; each of these had a different metabolite pro-
file reflecting the large variability in metabolite ratios for
this tumour group. The average N-acetyl aspartate/
creatine is high due to the presence of a very small
creatine peak in one of the cases, and would lead to
classification as a pilocytic astrocytoma if the tumour
classification scheme for the three most common tu-
mours was used. Inspecting the spectra for atypical
teratoid rhabdoid tumours confirmed no sharp peak at
2.0 ppm indicating the true N-acetyl aspartate level is
very low (Fig. 6), which would be unusual for a
pilocytic astrocytoma.
The diffuse astrocytoma spectrum (Fig. 6) exhibited a high
myo-inositol peak, and thus showed high values for ratios
containing myo-inositol. Although this tumour would be
Fig. 4 All data from original classification scheme and additional new
multicentre data are plotted on classification axes scatterplots. a N-acetyl
aspartate (NAA)/creatine (Cr) against myo-inositol (mIns)/NAAwith the
optimum cutoff value for separation of astrocytomas (white squares) from
ependymomas (black circles) and medulloblastomas (asterisks) is
indicated by horizontal and vertical dashed lines. b mIns/total choline
(tCho) against Cr/tCho shows the cutoff line required to separate
ependymomas (black circles) from medulloblastomas (asterisks)
Table 2 T-test results, determining whether mean values of ratios are
significantly different between groups, for re-optimising the classification
scheme for cerebellar tumours based on spectra from scanner software
P-value
Ratio Pilocytic
astrocytoma
vs. other
Medulloblastoma
vs. ependymoma
Cr/tCho 0.785 0.005
NAA/tCho <0.001 0.019
mIns/tCho 0.272 <0.001
NAA/Cr <0.001 0.212
mIns/Cr 0.330 0.075
mIns/NAA <0.001 0.013
LMM 0.9/tCho 0.015 0.184
LMM 1.3/tCho 0.436 0.296
LMM0.9/LMM 1.3 0.044 0.621
Cr creatine, LMM lipids and macromolecules, mIns myo-insoitol, NAA
N-acetyl aspartate, tCho total choline
Pediatr Radiol (2018) 48:1630–1641 1635
classified as an ependymoma using the updated peak height
classifier, these values are still lower that those typically seen
in ependymoma spectra. The spectrum of the diffuse astrocy-
toma also shows very small lipid and macromolecule peaks
and a peak at 2.6 ppm likely due to citrate, which may help
differentiate it from ependymoma.
The high-grade tumour has metabolite ratios close to the
cutoff value for distinguishing between medulloblastoma and
ependymoma spectra. The spectrum has features associated
with high-grade tumours, in particular, high lipids (Fig. 6). It
was not possible to obtain a definitive diagnosis for this tu-
mour from the histopathology.
The ganglioglioma was classified as a medulloblastoma on
step 2 of the updated peak height classifier. However, N-acetyl
aspartate/total choline is much higher than would be expected
for a medulloblastoma and the ratios myo-inositol/N-acetyl
aspartate and myo-inositol/creatine are lower than in
medulloblastoma.
Discussion
A multicentre study was performed to evaluate a previously
published diagnostic tool for classifying cerebellar tumours in
Fig. 5 The new optimised
classification decision scheme
uses all data. Cr creatine, mIns
myo-inositol, MRS magnetic
resonance spectroscopy, NAA N-
acetyl aspartate, tCho total
choline
Table 3 Area under the receiver
operator curve for prospective
study of scanner-produced
spectra of the three main
cerebellar tumour types
Ratio Pilocytic
astrocytoma
vs. all
Ependymoma vs. all Medulloblastoma vs. all Ependymoma vs.
medulloblastoma
Cr/tCho 0.849 0.944 0.562 0.918
NAA/tCho 0.882 0.659 0.872 0.830
mIns/tCho 0.677 0.985 0.608 0.978
NAA/Cr 0.998 0.749 0.818 0.610
mIns/Cr 0.624 0.696 0.716 0.862
mIns/NAA 0.912 0.894 0.615 0.840
LMM 0.9/tCho 0.834 0.560 0.795 0.670
LMM 1.3/tCho 0.690 0.596 0.635 0.661
LMM 0.9/LMM 1.3 0.739 0.640 0.639 0.525
Cr creatine, LMM lipids and macromolecules, mIns myo-insoitol, NAA N-acetyl aspartate, tCho total choline
1636 Pediatr Radiol (2018) 48:1630–1641
children according to their MR spectroscopy peak height ra-
tios [23]. A correct classification rate of 66% was obtained for
tumours with a diagnosis of pilocytic astrocytoma, medullo-
blastoma or ependymoma using the original method. As this
accuracy is lower than that reported for classifiers based on
pattern recognition in adult brain tumours [2–4, 6, 21], it is
important to explore whether there is an inherent weakness in
the approach or whether the parameters used were poorly
determined.
One weakness of the original analysis tool was that it was
based on a small dataset. Whilst mean values for metabolite
ratios can be calculated with some accuracy from small num-
bers of spectra, data variability is much more poorly deter-
mined. In this situation, the correct ratios to discriminate
among tumours may be selected, but the optimum cutoff
may be inaccurate. This problem is well demonstrated by the
discrimination between pilocytic astrocytomas and the com-
bined group of medulloblastomas and ependymomas.
Although the ratio N-acetyl aspartate/creatine was significant-
ly higher in pilocytic astrocytoma than the other tumours in
the original dataset and remained so in the new dataset, several
pilocytic astrocytomas in the new dataset had N-acetyl
aspartate/creatine with lower values than the original cutoff
of 4. Adjusting the cutoff to 2.2 allowed good discrimination
between pilocytic astrocytoma and the combined group of
medulloblastoma and ependymoma for the whole multicentre
dataset, and this value is likely to bemuch better determined in
the larger dataset.
Where there are very few spectra available for a giv-
en diagnosis, even mean values are poorly determined
and an inappropriate variable can be selected for dis-
crimination. This was the case for ependymomas in
the original scheme. Altering the cutoff will not im-
prove the accuracy in this situation; a more appropriate
variable is required. When the most discriminatory me-
tabolite ratio for ependymomas was determined from the
larger dataset and used to refine the diagnostic tool, a
classification rate of 90.6% was obtained, with 48 of 53
spectra correctly classified.
One of the greatest challenges in prospectively evaluating
the diagnostic tool on multicentre data was including spectra
acquired and processed on different scanners. Acquisition and
processing differs among scanners, with varying amounts of
baseline correction and level of water suppression leading to
challenges in accurately measuring peak heights. Despite this,
it was encouraging to see a classification rate for the 3 main
tumours of greater than 90% with the updated scanner classi-
fier, implying that straightforward peak measurement from
Table 5 Values for ratios in rare tumours of the cerebellum
Ratio Atypical teratoid rhabdoid tumour (n=3) Diffuse astrocytoma
(n=1)
Ganglioglioma
(n=1)
High-grade
tumour (n=1)
Mean Standard error
of the mean
Cr/tCho 0.123 0.050 1.245 0.651 0.590
NAA/tCho 0.584 0.299 1.129 1.005 0.967
mIns/tCho 0.386 0.293 1.299 0.499 0.872
NAA/Cr 4.502 0.580 0.907 1.543 1.638
mIns/NAA 0.547 0.222 1.150 0.496 0.903
mIns/Cr 2.593 1.318 1.043 0.766 1.479
LMM 0.9/tCho 0.661 0.451 0.152 0.283 0.521
LMM 1.3/tCho 0.838 0.515 0.000 0.448 1.902
LMM 0.9/LMM 1.3 1.799 1.644 0.000 0.632 0.274
Cr creatine, LMM lipids and macromolecules, mIns myo-insoitol, NAA N-acetyl aspartate, tCho total choline
Table 4 Classification of
cerebellar tumours using a
multicentre dataset
Diagnosis Number
of patients
Correct
classification
MR spectroscopy classification
Pilocytic
astrocytoma
Ependymoma Medulloblastoma
Pilocytic astrocytoma 16 94% 15 1 0
Ependymoma 8 88% 0 7 1
Medulloblastoma 29 90% 2 1 26
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scanner processed data can be used to analyse MR spectros-
copy from multiple scanners.
A further benefit conferred from a larger cohort is assess-
ment of rarer tumour types. Spectra for atypical teratoid
rhabdoid tumours and the high-grade tumour showed a strong
signal for lipids and macromolecules at 1.3 ppm in keeping
with their poor prognosis [24]. The diffuse astrocytoma spec-
trum closely resembled the ependymoma spectra due to the
presence of a high myo-inositol peak. This peak would be in
keeping with observations made in diffuse gliomas [25] and in
grade 2 gliomas [26, 27], all of which noted a strong signal
from this metabolite in keeping with glial lineage. Classifying
small numbers of many different tumour types is a challenge
for any classification scheme, particularly for a simple rule-
based classifier. We were, however, able to identify specific
changes in spectra from rare tumours that not only provided a
unique identifier, but were also consistent with known biolog-
ical characteristics of the tumours. Despite providing
interesting observations, it is difficult to draw firm conclusions
from data on rare cerebellar tumours. Although it may be
relatively straightforward to differentiate some rare lesions
from other more common tumours (e.g., atypical teratoid
rhabdoid tumour from pilocytic astrocytoma) on conventional
imaging, others are characterised by overlapping imaging
characteristics making them difficult to diagnose conclusively
without additional information. MR spectroscopy may be a
helpful addition to standard sequences in differentiating atyp-
ical teratoid rhabdoid tumour or ependymoma from medullo-
blastoma. It is important to remember thatMR spectroscopy is
not interpreted in isolation: rather, it is intended to enhance
conventional MRI reporting to facilitate diagnosis in ambigu-
ous cases.
Although short echo time MR spectroscopy provides more
information on additional metabolites than long echo timeMR
spectroscopy, there are difficulties associated with signals
from lipids and macromolecules. The frequent presence of a
Fig. 6 1H MR spectra from unusual main tumour types: (a) atypical
teratoid rhabdoid tumour, (b) diffuse astrocytoma of the cerebellum and
(c) high-grade lesion of the cerebellum. a.u arbitrary units, Cr creatine,
LMM lipids and macromolecules, mIns myo-inositol, NAA N-acetyl
aspartate, ppm parts per million, tCho total choline
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broad peak encompassing the region containing N-acetyl as-
partate (around 2.0 ppm) can make this metabolite difficult to
quantify. Using a “peak fitting” method (calculating metabo-
lite concentration from the area under the peak) in the original
dataset attributed N-acetyl aspartate to the entire broad peak,
considerably overestimating N-acetyl aspartate peak area. In
this study, the height of the narrow peak at around 2.0 ppm
was used for N-acetyl aspartate with the height of the broad
spectrum at 2.0 ppm used in cases where no narrow peak was
present. Although N-acetyl aspartate peak height values still
incorporate some macromolecular signal, they have a smaller
overestimation than peak area. This does not affect the validity
for classification, but should be considered when drawing
biological conclusions from N-acetyl aspartate values.
Although 1.5-T single-voxel spectroscopy remains a com-
monly used method, 3-T single-voxel spectroscopy is becom-
ing increasingly used.Whilst the general approach used in this
paper is applicable to 3-T single-voxel spectroscopy, the spe-
cific algorithmwould need to be generated and validated on 3-
T data. In particular, multiplet peaks such as myo-inositol
have a different appearance in 3-T compared with 1.5-T
single-voxel spectroscopy. The current method could, howev-
er, be applied directly to data acquired using 1.5-Tmulti-voxel
MR spectroscopy and may identify areas that are most repre-
sentative of tumour.
Results of this study correlate with findings of previous
studies and are biologically plausible in the context of tu-
mour behaviour. Our finding of high N-acetyl aspartate/
creatine in pilocytic astrocytoma is in accordance with re-
ports from several studies in adults that found this ratio to
be high in low-grade tumours with a good prognosis [2, 6,
28]. Evidence suggests N-acetyl aspartate/creatine is a good
discriminator between high- and low-grade childhood tu-
mours [29]. N-acetyl aspartate is a marker of neuronal in-
tegrity often considered to indicate normal brain tissue,
with decreased levels in spectra of more highly malignant
brain tumours [5, 7, 23, 30, 31]. Medulloblastoma and
ependymoma had lower N-acetyl aspartate/creatine, in ac-
cordance with reports of low N-acetyl aspartate in malig-
nancy and as a significant discriminator between
ependymoma and other tumours [10]. This finding is also
in agreement with reports of significantly lower levels of
creatine in pilocytic astrocytoma compared to other tumour
types [10]. Creatine, present in neuronal and glial cells, is
involved in energy storage and metabolism and although
this metabolite is stable in normal brain, levels vary in
pathological states. The mean creatine of untreated tumors
has been found to be half that of normal brain tissue both
in vivo and in vitro [32] with reports of decreased creatine
levels in gliomas [10, 11]. Concentrations of this metabolite
may be related to tumour cell type rather than grade as no
pattern of reduced or increased creatine has been reported
in more malignant tumours [10].
The low myo-inositol/N-acetyl aspartate found in pilocytic
astrocytoma is consistent with reports of pilocytic astrocytoma
exhibiting low myo-inositol with a significantly lower myo-
inositol/total choline than other tumours [10]. The role of
myo-inositol is poorly understood, although interestingly this
metabolite has been found to be present in high concentration
in other astrocytoma types supporting the theory of myo-
inositol being an astrocyte marker [33]. Our finding of high
myo-inositol/total choline in ependymoma agrees with earlier
reports of high myo-inositol in ependymoma [33]. In this
study, myo-inositol was particularly high in grade II
ependymoma. The low myo-inositol/total choline in medullo-
blastoma in this study is in accordance with findings of par-
ticularly high total choline levels in medulloblastoma [10].
Choline is involved in membrane synthesis and breakdown,
increasing with cell proliferation in highly malignant tumours
[5, 18, 34].
Diagnosing paediatric brain lesions is complex and contin-
ually evolving, with the advent of molecular subtyping provid-
ing more detailed classification of cerebellar tumours.
According to the most recent World Health Organisation clas-
sification [35], medulloblastomas may be classified into four
distinct subtypes corresponding to molecular characteristics.
The histopathological classification of medulloblastoma has,
however, been retained and is in continued use in clinical prac-
tice. Histopathological and molecular classifications may be
used independently. Although molecular subtyping may influ-
ence treatment strategy and intensity in the future, research into
the best way to use this information to determine management
is ongoing and medulloblastoma is generally not yet treated
according to genetic profile outside a clinical trial. As this
was a relatively small, multicentre study with samples collected
over a long period of time, molecular data were unavailable
precluding further exploration at this stage. Determining mo-
lecular subtype noninvasively is an important goal and there is
already published evidence that this can be achieved to some
extent by both standard MRI and MR spectroscopy [36, 37]. A
larger study would be necessary to mapMR spectroscopy peak
heights to enable diagnosis of different genetic profiles. It
would be interesting to explore the role of MR spectroscopy
and peak height measurement further as evidence for treatment
according to novel diagnostic criteria evolves.
The tumour classifier is a simple and fast way of
assessing a spectrum and is ideal in a clinical scenario
when sophisticated analysis tools are not available. The
modified classifier described offers a high classification rate
between the three main types of cerebellar tumours. This
scheme does not incorporate information from the whole
set of metabolites detected, which could aid in classifying
both common and rarer tumours. Incorporating this infor-
mation in a quantitative method would, however, require
more sophisticated analysis tools currently not readily ac-
cessible in routine clinical practice.
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Conclusion
A previously published tool for aiding the diagnosis of child-
hood cerebellar tumours using peak height measurements of
MR spectroscopy data was evaluated prospectively on
multicentre data and found to have only moderate accuracy.
A tool developed from an expanded dataset resulted in accu-
rate classification, implying that sample size is an important
prerequisite. This new noninvasive diagnostic aid may pro-
vide accurate results fromMR spectroscopy peak height mea-
surement across different scanners. Prospective evaluation
should be conducted to determine the true accuracy of this
promising diagnostic tool.
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